Compare BOSC & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOSC | INTS |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 24.0M |
| IPO Year | 1996 | 2023 |
| Metric | BOSC | INTS |
|---|---|---|
| Price | $4.87 | $0.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $2.25 |
| AVG Volume (30 Days) | 59.5K | ★ 1.2M |
| Earning Date | 11-25-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.29 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $48,333,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.71 | ★ N/A |
| Revenue Growth | ★ 19.49 | N/A |
| 52 Week Low | $3.30 | $0.19 |
| 52 Week High | $6.72 | $2.80 |
| Indicator | BOSC | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 45.43 |
| Support Level | $4.80 | $0.39 |
| Resistance Level | $5.16 | $0.44 |
| Average True Range (ATR) | 0.25 | 0.02 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 55.23 | 17.79 |
BOS Better Online Solutions Ltd is a provider of Intelligent Robotics and Supply Chain solutions for enterprises. The company manages its business in three reportable divisions: the Intelligent Robotics segment, the RFID Division segment, and the Supply Chain Solutions segment. The majority of revenue derives from Supply Chain Solutions which distributes electro-mechanical components, mainly to customers in the aerospace, defense, and other industries, and is a supply chain service provider for aviation customers that seek a comprehensive solution to their components-supply needs. Geographically company derives the majority of its revenue from Israel.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.